We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Submit a Manuscript to the Journal
Human Vaccines & Immunotherapeutics

For a Special Issue on
Immunotherapy of Renal-Cell Carcinoma

Manuscript deadline
31 March 2023

Cover image - Human Vaccines & Immunotherapeutics

Special Issue Editor(s)

Ernesto Rossi, Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
[email protected]

Submit an ArticleVisit JournalArticles

Immunotherapy of Renal-Cell Carcinoma

Renal-cell carcinoma (RCC) is the most common type of kidney cancer accounting for >100,000 annual deaths globally and rising. With several approved products, immunotherapy plays an important role in the management of RCC, and its significance is expected to increase. We are looking for articles investigating:

  • RCC immunotherapy in use and in clinical trials

  • Novel approaches to RCC immunotherapy

  • (Neo)adjuvant immunotherapy and combination regimens

  • RCC vaccines and personalized immunotherapies

  • Biomarkers and predictive factors

  • Preclinical models, trial design and regulatory issues

Submission Instructions

  • Select "Immunotherapy of RCC" when submitting your paper to the Submission Portal

  • Research papers, Reviews and Commentaries will be considered for publication

  • Papers will be published online as they are accepted

Instructions for AuthorsSubmit an Article

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.